Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262116 · ClinicalTrials.gov registry record · Phase 2
Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03262116: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03262116 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03262116, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.
Interventions
- DEVICE Bionic Pancreas
- DRUG Humalog
- DRUG Novolog
- DRUG BC222 insulin lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2019-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262116
The ClinicalTrials.gov registry entry for NCT03262116 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bionic Pancreas is the first listed.
NCT03262116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03262116 about?
NCT03262116 is a clinical study titled "Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas". Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.
What is the current status of trial NCT03262116?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-03-19. Estimated completion is 2019-07-23.
What interventions are being tested in trial NCT03262116?
The interventions under investigation include: Bionic Pancreas (DEVICE), Humalog (DRUG), Novolog (DRUG), BC222 insulin lispro (DRUG).
Who is sponsoring clinical trial NCT03262116?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.